Skip to Content
  • Previous Rank255
  • Revenues ($M)$40,122
  • Revenue Percent Change0.8%
  • Profits ($M)$2,394.00
  • Profits Percent Change-38.9%
  • Assets ($M)$87,872.00
  • Employees69,000

The pharmaceutical giant raked in $40.1 billion in global sales in 2017, an increase of 1% from the year before. Merck’s superstar cancer immunotherapy drug Keytruda has continued to be the big performer; it alone brought in $1.46 billion in the first quarter of this year—an increase of 150% from the same time period last year. Success has been a mixed blessing, however. Keytruda now plays an outsize role in Merck’s portfolio, responsible for about 15% of the company’s sales. Moreover, plans to expand the drug’s applications have hit a snag: A collaboration with the biotech research firm Incyte to combine the drug with another experimental therapy was halted.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Kenneth C. Frazier
Health Care
HQ Location
Kenilworth, N.J.
Years on Global 500 List24

Merck Rank History

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$40,1220.8%
Profits ($M)$2,394.00-38.9%
Assets ($M)$87,872.00-
Total Stockholder Equity ($M)$34,336.00-

Profit Ratios

Profit as % of Revenues6%
Profits as % of Assets2.7%
Profits as % of Stockholder Equity7%